PS
PSNL.US Personalis Inc
- Market cap
- USD 1.60B
- P/E
- -
- P/B
- 7.54x
- ROE
- -59.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PSNL.US undervalued?
Graham numberThe Graham number of Personalis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Personalis Inc fundamental analysis
No fundamental analysis for Personalis Inc yet.
Personalis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional…
Full company profilePersonalis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Personalis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.39M | 37.8M | 65.2M | 78.6M | 85.5M | 65.0M | 73.5M | 84.6M | 69.6M | 84.6M |
| Gross Profit | -2.34M | 11.8M | 22.1M | 20.1M | 31.7M | 13.4M | 18.2M | 26.8M | 15.8M | 15.5M |
| Operating Income | -22.2M | -13.8M | -22.4M | -42.1M | -65.4M | -116M | -96.3M | -68.3M | -88.1M | -135M |
| EBITDA | -21.1M | -14.9M | -19.2M | -35.5M | -59.0M | -105M | -96.8M | -70.3M | -71.0M | -117M |
| Net Income | -23.6M | -19.9M | -25.1M | -41.3M | -65.2M | -113M | -108M | -81.3M | -81.3M | -127M |
| EPS | -1.08 | -0.91 | -1.39 | -1.20 | -1.49 | -2.48 | -2.25 | -1.37 | -0.91 | -1.19 |
| Balance Sheet | ||||||||||
| Total Assets | 33.6M | 41.7M | 157M | 245M | 397M | 293M | 225M | 270M | 334M | 292M |
| Total Liabilities | 126M | 148M | 50.6M | 49.9M | 86.2M | 74.6M | 95.7M | 67.3M | 73.0M | 78.9M |
| Shareholders' Equity | -92.6M | -106M | 107M | 195M | 310M | 218M | 129M | 203M | 261M | 213M |
| Cash & Short-term Investments | 22.6M | 19.7M | 128M | 203M | 287M | 168M | 114M | 185M | 240M | 191M |
| Total Debt | 17.8M | 5.68M | 2.00M | 11.0M | 58.3M | 48.7M | 47.7M | 44.2M | 39.9M | 37.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 290K | 5.57M | -18.1M | -42.7M | -70.8M | -70.2M | -56.3M | -45.2M | -74.9M | -100M |
| Capital Expenditure | 5.16M | 7.85M | 8.38M | 3.25M | 11.1M | 49.9M | 10.9M | 1.60M | 4.50M | 13.4M |
| Free Cash Flow | -4.87M | -2.28M | -26.5M | -45.9M | -81.9M | -120M | -67.2M | -46.8M | -79.5M | -114M |
| Ratios | ||||||||||
| ROE | - | - | -23.5% | -21.2% | -21.0% | -51.9% | -83.7% | -40.0% | -31.1% | -59.9% |
| ROA | -70.3% | -47.7% | -15.9% | -16.9% | -16.4% | -38.7% | -48.1% | -30.1% | -24.3% | -43.7% |
| Net Profit Margin | -251.2% | -52.6% | -38.5% | -52.5% | -76.3% | -174.2% | -147.4% | -96.1% | -116.7% | -150.6% |
| Debt to Equity | - | - | 0.02x | 0.06x | 0.19x | 0.22x | 0.37x | 0.22x | 0.15x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Personalis Inc dividends
Personalis Inc has not paid dividends in the last 9 fiscal years.
Who owns Personalis Inc
- Insiders 25.60%
- Institutions 65.53%
- Public & others 8.86%
- Shares outstanding 108M
- Free float 73.9M
Top funds holding PSNL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.45M | 2.26% | +14.33% | Sep 2026 |
| iShares Russell 2000 ETF | 1.85M | 1.70% | 0.00% | Oct 2026 |
| abrdn Healthcare Investors | 1.36M | 1.26% | -37.32% | Oct 2026 |
| ARK Genomic Revolution ETF | 1.17M | 1.08% | +0.58% | Oct 2026 |
| Columbia Small Cap Growth Inst | 938K | 0.87% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 775K | 0.72% | -40.67% | Oct 2026 |
| Fidelity Small Cap Index | 744K | 0.69% | +0.08% | Aug 2026 |
| T. Rowe Price New Horizons | 701K | 0.65% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 686K | 0.63% | 0.00% | Oct 2026 |
| AZ Fd 1 - AZ Eq - Amer Opps A-EUR Acc | 608K | 0.56% | +4.59% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 579K | 0.53% | +1.62% | Sep 2026 |
| iShares Biotechnology ETF | 561K | 0.52% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 421K | 0.39% | +8.14% | Sep 2026 |
| Nuveen Quant Small/Mid Cap Eq R6 | 403K | 0.37% | +160.22% | Sep 2026 |
| RBC Private U.S. Small-Cap Eqty Pool F | 387K | 0.36% | +0.53% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 353K | 0.33% | +0.24% | Oct 2026 |
| CREF Total Global Stock Account R3 | 315K | 0.29% | +150.45% | Sep 2026 |
| Fidelity Extended Market Index | 307K | 0.28% | -10.13% | Sep 2026 |
| DFA U.S. Small Cap I | 261K | 0.24% | -1.03% | Sep 2026 |
| DFA US Micro Cap I | 239K | 0.22% | 0.00% | Sep 2026 |
Top institutions holding PSNL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Merck & Co Inc | 14.0M | 12.96% | 0.00% | Jun 2026 |
| ARK Investment Management LLC | 8.27M | 7.63% | +4.12% | Jun 2026 |
| BlackRock Inc | 7.08M | 6.53% | +31.40% | Jun 2026 |
| Lightspeed Management Co LLC | 6.10M | 5.63% | -25.23% | Jun 2026 |
| Ameriprise Financial Inc | 6.09M | 5.61% | -19.84% | Jun 2026 |
| Deep Track Capital, LP | 4.00M | 3.69% | +33.33% | Jun 2026 |
| Aberdeen Group PLC | 3.48M | 3.21% | -7.11% | Sep 2026 |
| Vanguard Capital Management, LLC | 3.01M | 2.78% | +4.94% | Jun 2026 |
| Casdin Capital, LLC | 2.55M | 2.35% | +59.38% | Jun 2026 |
| Kennedy Capital Management Inc | 2.36M | 2.18% | +8.28% | Jun 2026 |
| Geode Capital Management, LLC | 1.82M | 1.68% | +40.44% | Jun 2026 |
| Bank of America Corp | 1.82M | 1.68% | +1,535.62% | Jun 2026 |
| AIGH Capital Management, LLC | 1.72M | 1.58% | -40.86% | Jun 2026 |
| Blue Water Life Science Advisors, LLC | 1.68M | 1.55% | 0.00% | Jun 2026 |
| State Street Corp | 1.49M | 1.37% | +31.12% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.27M | 1.17% | +435.55% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.23M | 1.14% | -17.60% | Sep 2026 |
| The Goldman Sachs Group Inc | 931K | 0.86% | +26.30% | Jun 2026 |
| HRT FINANCIAL LLC | 931K | 0.86% | +345.60% | Jun 2026 |
| Nuveen, LLC | 753K | 0.69% | +119.20% | Jun 2026 |
Personalis Inc company profile
- Company name
- Personalis Inc
- Ticker
- PSNL.US
- Exchange
- USA Stocks
- Listed since
- Jun 20, 2019
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 259
- Fiscal year end
- December
- Address
- 6600 Dumbarton Circle, Fremont, CA, United States, 94555
- Phone
- 650 752 1300
- Website
- personalis.com
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Personalis Inc management
10- Mr. Christopher M. HallCEO & Director · born 1969
- Dr. Richard Chen M.D., M.S.President & Chief Medical Officer · born 1971
- Mr. Aaron L. TachibanaCFO & COO · born 1961
- Dr. Russ B. Altman M.D., Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board · born 1971
- Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board
- Mr. Ashish KheterpalSenior VP & Chief Information Officer
- Mr. Stephen M. Moore J.D.Senior VP, Chief Legal Officer & Corporate Secretary · born 1972
- Dr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Science
- Mr. Stephane Mouradian Ph.D.Senior Vice President of Business Development